Inovio Pharmaceuticals (INO) Operating Leases (2019 - 2025)
Historic Operating Leases for Inovio Pharmaceuticals (INO) over the last 7 years, with Q3 2025 value amounting to $10.0 million.
- Inovio Pharmaceuticals' Operating Leases fell 1948.57% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year decrease of 1948.57%. This contributed to the annual value of $9.4 million for FY2024, which is 1508.55% down from last year.
- According to the latest figures from Q3 2025, Inovio Pharmaceuticals' Operating Leases is $10.0 million, which was down 1948.57% from $10.7 million recorded in Q2 2025.
- Inovio Pharmaceuticals' Operating Leases' 5-year high stood at $19.8 million during Q1 2021, with a 5-year trough of $9.4 million in Q4 2024.
- Over the past 5 years, Inovio Pharmaceuticals' median Operating Leases value was $13.4 million (recorded in 2024), while the average stood at $14.2 million.
- Per our database at Business Quant, Inovio Pharmaceuticals' Operating Leases tumbled by 651.29% in 2024 and then plummeted by 1948.57% in 2025.
- Over the past 5 years, Inovio Pharmaceuticals' Operating Leases (Quarter) stood at $15.5 million in 2021, then fell by 18.14% to $12.7 million in 2022, then fell by 12.83% to $11.0 million in 2023, then dropped by 15.09% to $9.4 million in 2024, then grew by 6.96% to $10.0 million in 2025.
- Its Operating Leases stands at $10.0 million for Q3 2025, versus $10.7 million for Q2 2025 and $11.3 million for Q1 2025.